Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Comparator Requirement For Interchangeable Biosimilars Would Hurt Industry

Executive Summary

US FDA’s recommendation against use of foreign-licensed reference products in clinical switching studies would result in procurement challenges and higher costs for biosimilar developers while also limiting where such studies could be conducted, some companies say.

You may also be interested in...



Make Interchangeability Great Again: Biosimilar Switching Studies Need US Comparators

Sandoz, which used an EU-approved comparator in the switch study for its biosimilar Erelzi, might have to redo the trial in light of FDA’s draft guidance.

Sandoz's Multi-Switch Biosimilar Trials: A View To Interchangeability?

Company's application development seems to be outpacing FDA's policy development in next step along the 351(k) pathway.

REMS That Block Generics Are ‘Major’ Problem For FDA, Jenkins Says

Chief of new drugs office notes unintended consequence of safety legislation is thwarting development of ANDAs and biosimilars.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB002202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel